I en analyse, hvor der justeredes for potential bias fra ikke skemalagte vurderinger, var raten af sygdomsprogression eller dødsfald hos patienterne, der fik Vectibix, reduceret med 40% sammenlignet med patienter, som fik BSC (risikoratio = 0, 60 (95% CI 0, 49; 0, 74), stratificeret log- rank p < 0, 0001).
In an analysis adjusting for potential bias from unscheduled assessments, the rate of disease progression or death in patients who received Vectibix was reduced by 40% relative to patients that received BSC [Hazard Ratio = 0.60, (95% CI 0.49, 0.74), stratified log-rank p < 0.0001].